These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 8837524)
21. [Evaluation of disk diffusion test for carbapenem sensitivity in Acinetobacter baumannii and Pseudomonas aeruginosa strains]. Akan OA; Uysal S Mikrobiyol Bul; 2005 Jul; 39(3):273-9. PubMed ID: 16358486 [TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083 [TBL] [Abstract][Full Text] [Related]
23. Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates? Tamma PD; Wang R; Lewis S; Opene BNA; Simner PJ Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1378-1379. PubMed ID: 28965496 [No Abstract] [Full Text] [Related]
24. [A novel carbapenem active against imipenem resistant strains of Pseudomonas aeruginosa]. Sazykin YuO Antibiot Khimioter; 1997; 42(8):42. PubMed ID: 9412413 [No Abstract] [Full Text] [Related]
25. Resistance emergence among P. aenrginosa in a rat thigh-abscess model. Comparison of imipenem and meropenem treatment. Karadenizli A; Kolayli F; Okay E; Ergen K; Oz S; Savli H; Leblebicioglu H; Vahaboglu H New Microbiol; 2003 Jul; 26(3):275-80. PubMed ID: 12901424 [TBL] [Abstract][Full Text] [Related]
26. Antibiotic resistance and molecular typing of Pseudomonas aeruginosa: focus on imipenem. de Freitas AL; Barth AL Braz J Infect Dis; 2002 Feb; 6(1):1-7. PubMed ID: 11980597 [TBL] [Abstract][Full Text] [Related]
27. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance]. Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699 [TBL] [Abstract][Full Text] [Related]
28. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Farra A; Islam S; Strålfors A; Sörberg M; Wretlind B Int J Antimicrob Agents; 2008 May; 31(5):427-33. PubMed ID: 18375104 [TBL] [Abstract][Full Text] [Related]
29. Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. Coquet L; Junter GA; Jouenne T J Antimicrob Chemother; 1998 Dec; 42(6):755-60. PubMed ID: 10052899 [TBL] [Abstract][Full Text] [Related]
30. [In vitro study of the bacteriostatic and bactericidal activity of meropenem against strains of Pseudomonas aeruginosa multiresistant to antibiotics]. Delisle F; Lesage D; Barakett V; Richard G; Petit JC Pathol Biol (Paris); 1996 May; 44(5):337-40. PubMed ID: 8758471 [TBL] [Abstract][Full Text] [Related]
31. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. Chen HY; Livermore DM J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068 [TBL] [Abstract][Full Text] [Related]
32. A study of the mechanisms involved in imipenem resistance in Pseudomonas aeruginosa isolates from Japan. Stunt RA; Thomson CJ; Payne DJ; Amyes SG J Antimicrob Chemother; 1998 Aug; 42(2):272-3. PubMed ID: 9738853 [No Abstract] [Full Text] [Related]
33. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff DA; Nicolau DP Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574 [TBL] [Abstract][Full Text] [Related]
34. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Trautmann M; Heinemann M; Zick R; Möricke A; Seidelmann M; Berger D Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):754-60. PubMed ID: 9923514 [TBL] [Abstract][Full Text] [Related]
36. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany. Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R; Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334 [TBL] [Abstract][Full Text] [Related]
37. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years]. Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905 [TBL] [Abstract][Full Text] [Related]
38. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925 [TBL] [Abstract][Full Text] [Related]
39. Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. Chin NX; Neu HC Chemotherapy; 1987; 33(3):183-8. PubMed ID: 3109815 [TBL] [Abstract][Full Text] [Related]